231 related articles for article (PubMed ID: 33574401)
1. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial.
How JA; Jazaeri AA; Soliman PT; Fleming ND; Gong J; Piha-Paul SA; Janku F; Stephen B; Naing A
Sci Rep; 2021 Feb; 11(1):3667. PubMed ID: 33574401
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
Shapira-Frommer R; Mileshkin L; Manzyuk L; Penel N; Burge M; Piha-Paul SA; Girda E; Lopez Martin JA; van Dongen MGJ; Italiano A; Xu L; Jin F; Norwood K; Ott PA
Gynecol Oncol; 2022 Aug; 166(2):211-218. PubMed ID: 35361487
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature.
Shields LBE; Gordinier ME
Gynecol Obstet Invest; 2019; 84(1):94-98. PubMed ID: 30016784
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.
Hahn AW; Chahoud J; Campbell MT; Karp DD; Wang J; Stephen B; Tu SM; Pettaway CA; Naing A
Invest New Drugs; 2021 Oct; 39(5):1405-1410. PubMed ID: 33770291
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
Naumann RW; Hollebecque A; Meyer T; Devlin MJ; Oaknin A; Kerger J; López-Picazo JM; Machiels JP; Delord JP; Evans TRJ; Boni V; Calvo E; Topalian SL; Chen T; Soumaoro I; Li B; Gu J; Zwirtes R; Moore KN
J Clin Oncol; 2019 Nov; 37(31):2825-2834. PubMed ID: 31487218
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma.
Yeku O; Russo AL; Lee H; Spriggs D
J Transl Med; 2020 Sep; 18(1):350. PubMed ID: 32928237
[TBL] [Abstract][Full Text] [Related]
9. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
10. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
11. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Dibbern ME; Bullock TN; Jenkins TM; Duska LR; Stoler MH; Mills AM
Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
[TBL] [Abstract][Full Text] [Related]
12. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
How JA; Jazaeri A; Westin SN; Sood AK; Ramondetta LM; Xu M; Abonofal A; Karp DD; Subbiah V; Stephen B; Rodon JA; Yang F; Naing A
Invest New Drugs; 2021 Jun; 39(3):829-835. PubMed ID: 33415580
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Adams S; Loi S; Toppmeyer D; Cescon DW; De Laurentiis M; Nanda R; Winer EP; Mukai H; Tamura K; Armstrong A; Liu MC; Iwata H; Ryvo L; Wimberger P; Rugo HS; Tan AR; Jia L; Ding Y; Karantza V; Schmid P
Ann Oncol; 2019 Mar; 30(3):405-411. PubMed ID: 30475947
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Adams S; Schmid P; Rugo HS; Winer EP; Loirat D; Awada A; Cescon DW; Iwata H; Campone M; Nanda R; Hui R; Curigliano G; Toppmeyer D; O'Shaughnessy J; Loi S; Paluch-Shimon S; Tan AR; Card D; Zhao J; Karantza V; Cortés J
Ann Oncol; 2019 Mar; 30(3):397-404. PubMed ID: 30475950
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy.
Chinn Z; Stoler MH; Mills AM
Histopathology; 2019 Jan; 74(2):256-268. PubMed ID: 30067880
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report.
Egger EK; Ralser DJ; Lindner K; Recker F; Marinova M; Savchenko O; Lau JF; Mustea A
Front Immunol; 2021; 12():686879. PubMed ID: 34367146
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
18. Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels.
Weng X; Luo S; Lin S; Zhong L; Li M; Xin R; Huang P; Xu X
Oncol Res; 2020 Mar; 28(2):117-125. PubMed ID: 31610828
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
